LEADER 05657nam 2200685 450 001 9910139118703321 005 20200520144314.0 010 $a1-118-77816-2 010 $a1-118-77815-4 035 $a(CKB)2550000001256706 035 $a(EBL)1662193 035 $a(OCoLC)857664391 035 $a(MiAaPQ)EBC1662193 035 $a(Au-PeEL)EBL1662193 035 $a(CaPaEBR)ebr10856828 035 $a(CaONFJC)MIL588429 035 $a(PPN)194568741 035 $a(EXLCZ)992550000001256706 100 $a20140415h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aCollaborative innovation in drug discovery $estrategies for public and private partnerships /$fedited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others] 210 1$aHoboken, New Jersey :$cWiley,$d2014. 210 4$dİ2014 215 $a1 online resource (760 p.) 225 1 $aWiley Series on Technologies for the Pharmaceutical Industry 300 $aDescription based upon print version of record. 311 $a0-470-91737-7 311 $a1-306-57178-2 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry 327 $a2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References 327 $a4: The Changing Face of Innovation in Drug DiscoveryIntroduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug Discovery; Target Identification and Target Validation; Hit Identification: The First Stage in Drug Hunting; Lead Optimization: A Field to Which Companies Must Commit Major Amounts of Human and Financial Resources; Preclinical Assessment: Select the First-in-Class and/or Best-in-Class Drug Candidate for Clinical Development; An Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery 327 $aFuture Perspectives: Where Is Innovation Leading?References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public Domain; Effective Management of Academia-Pharma Collaborations; Concluding Remarks; References 327 $a6: A Perspective on the Evolution of Collaborative Drug Discovery and Future ChallengesEvolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Maryland Industrial Partnerships (MIPS) Program; Funding for Collaborations with Academia 327 $aNew Initiatives to Transform University-Industry Collaborations 330 $aCan academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving d 410 0$aWiley series on technologies for the pharmaceutical industry. 606 $aDrug Discovery 606 $aPublic-Private Sector Partnerships 606 $aDrug development 606 $aPublic-private sector cooperation 615 0$aDrug Discovery. 615 0$aPublic-Private Sector Partnerships. 615 0$aDrug development. 615 0$aPublic-private sector cooperation. 676 $a615.1/9 702 $aChaguturu$b Rathnam 702 $aFerid Murad$b Nobel Laureate 702 $aAsadullah$b Khusru 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139118703321 996 $aCollaborative innovation in drug discovery$92108446 997 $aUNINA